Case-Fatality Ratio and Effectiveness of Ribavirin Therapy Among Hospitalized Patients in China Who Had Severe Fever With Thrombocytopenia Syndrome
Open Access
- 20 August 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 57 (9), 1292-1299
- https://doi.org/10.1093/cid/cit530
Abstract
Background. The wide distribution and high case-fatality ratio of severe fever with thrombocytopenia syndrome (SFTS) have made it a significant public health problem. This study was designed to identify the predictors of fatal outcomes and to evaluate the effectiveness of antiviral therapy in treating SFTS virus (SFTSV)–infected patients. Methods. A cross-sectional study was performed in a general hospital located in Xinyang city, whereas the largest number of patients with SFTS in China were treated during 2011–2012. The primary outcome for the treatment effect analysis was death. Other outcomes included sequential platelet levels and viral loads observed throughout the hospitalization and the interval between the initiation of ribavirin therapy and the return of the platelet count to a normal level. Results. A total of 311 SFTSV-infected patients were included in the study. The most frequent clinical presentations were fever, weakness, myalgia, and gastrointestinal symptoms. Each patient had thrombocytopenia, leukopenia, or both. The case-fatality ratio (CFR) was 17.4% (95% confidence interval [CI], 13.1%–21.6%). Older age (odds ratio [OR], 1.061; 95% CI, 1.023–1.099; P = .001), decreased level of consciousness (OR, 5.397; 95% CI, 2.660–10.948; P < .001), and elevated levels of lactate dehydrogenase (>1200 U/L; OR, 2.620; 95% CI, 1.073–6.399; P = .035) and creatine kinase (>800 U/L; OR, 2.328; 95% CI, 1.129–4.800; P = .022) were significantly associated with fatal outcome. The CFRs were similar between patients who received ribavirin and those who did not. Ribavirin treatment showed no significant effect on either platelet counts or viral loads during hospitalization of patients with fatal or nonfatal cases. Conclusions. These findings can improve knowledge about the characteristics of patients with fatal outcomes and the use of antiviral drug for SFTS.Keywords
This publication has 14 references indexed in Scilit:
- Evolutionary and molecular analysis of the emergent severe fever with thrombocytopenia syndrome virusEpidemics, 2013
- Clinical Progress and Risk Factors for Death in Severe Fever with Thrombocytopenia Syndrome PatientsThe Journal of Infectious Diseases, 2012
- A New Phlebovirus Associated with Severe Febrile Illness in MissouriNew England Journal of Medicine, 2012
- Host Cytokine Storm Is Associated With Disease Severity of Severe Fever With Thrombocytopenia SyndromeThe Journal of Infectious Diseases, 2012
- Cytokine and Chemokine Levels in Patients with Severe Fever with Thrombocytopenia Syndrome VirusPLOS ONE, 2012
- Hemorrhagic Fever Caused by a Novel Bunyavirus in China: Pathogenesis and Correlates of Fatal OutcomeClinical Infectious Diseases, 2011
- Fever with Thrombocytopenia Associated with a Novel Bunyavirus in ChinaNew England Journal of Medicine, 2011
- Mechanisms of action of ribavirin against distinct virusesReviews in Medical Virology, 2005
- The Efficacy of Oral Ribavirin in the Treatment of Crimean-Congo Hemorrhagic Fever in IranClinical Infectious Diseases, 2003
- Ribavirin - current status of a broad spectrum antiviral agentExpert Opinion on Pharmacotherapy, 2001